Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy

Geraldine Rousvoal, Ming Sing Si, Macy Lau, Sally Zhang, Gerald J. Berry, Mona G. Flores, Paul S. Changelian, Bruce A. Reitz, Dominic C. Borie

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Janus kinase 3 (JAK3) mediates signal transduction from cytokine receptors using the common γ chain. The rationally designed inhibitor of JAK3, CP-690,550, prevents acute allograft rejection in rodents and in nonhuman primates. Here we investigated the ability of CP-690,550, to prevent allograft vasculopathy in a rodent model of aorta transplantation. Aortas from AxC Irish (RT1a) or Lewis (RT1l) rats were heterotopically transplanted into the infra-renal aorta of Lewis recipients and harvested at 28 or 56 days. Treated recipients received CP-690,550 by osmotic pumps (mean drug exposure of 110 ± 38 ng/ml). Significant intimal hyperplasia was demonstrated in untreated allografts when compared with isografts at 28 days (2.08 ± 0.85% vs. 0.43 ± 0.2% luminal obliteration, respectively, P = 0.001) and 56 days (5.3 ± 2.4% vs. 0.38 ± 0.3%, P = 0.002). Treatment caused a 51% reduction in intimal hyperplasia at day 56. CP-690,550-treated animals also had a significant reduction of donor-specific IgG production and of the gene expression for suppressor of cytokine signaling-3 and with unchanged levels of expression of RANTES, IP-10 and transforming growth factor-β1. These results are the first to show that JAK3 blockade by CP-690,550 effectively prevents allograft vasculopathy in this rat model of aorta transplantation.

Original languageEnglish (US)
Pages (from-to)1014-1021
Number of pages8
JournalTransplant International
Volume19
Issue number12
DOIs
StatePublished - Dec 2006
Externally publishedYes

Fingerprint

Janus Kinase 3
Allografts
Aorta
Tunica Intima
Hyperplasia
Rodentia
Transplantation
Isografts
Chemokine CCL5
Cytokine Receptors
Transforming Growth Factors
Primates
Signal Transduction
Immunoglobulin G
tofacitinib
Cytokines
Kidney
Gene Expression
Pharmaceutical Preparations

Keywords

  • Aorta transplantation
  • Chronic rejection
  • CP-690,550
  • Janus kinase 3

ASJC Scopus subject areas

  • Transplantation

Cite this

Rousvoal, G., Si, M. S., Lau, M., Zhang, S., Berry, G. J., Flores, M. G., ... Borie, D. C. (2006). Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy. Transplant International, 19(12), 1014-1021. https://doi.org/10.1111/j.1432-2277.2006.00387.x

Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy. / Rousvoal, Geraldine; Si, Ming Sing; Lau, Macy; Zhang, Sally; Berry, Gerald J.; Flores, Mona G.; Changelian, Paul S.; Reitz, Bruce A.; Borie, Dominic C.

In: Transplant International, Vol. 19, No. 12, 12.2006, p. 1014-1021.

Research output: Contribution to journalArticle

Rousvoal, G, Si, MS, Lau, M, Zhang, S, Berry, GJ, Flores, MG, Changelian, PS, Reitz, BA & Borie, DC 2006, 'Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy', Transplant International, vol. 19, no. 12, pp. 1014-1021. https://doi.org/10.1111/j.1432-2277.2006.00387.x
Rousvoal, Geraldine ; Si, Ming Sing ; Lau, Macy ; Zhang, Sally ; Berry, Gerald J. ; Flores, Mona G. ; Changelian, Paul S. ; Reitz, Bruce A. ; Borie, Dominic C. / Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy. In: Transplant International. 2006 ; Vol. 19, No. 12. pp. 1014-1021.
@article{3b5b36cf9ac547148c98e94247a8c513,
title = "Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy",
abstract = "Janus kinase 3 (JAK3) mediates signal transduction from cytokine receptors using the common γ chain. The rationally designed inhibitor of JAK3, CP-690,550, prevents acute allograft rejection in rodents and in nonhuman primates. Here we investigated the ability of CP-690,550, to prevent allograft vasculopathy in a rodent model of aorta transplantation. Aortas from AxC Irish (RT1a) or Lewis (RT1l) rats were heterotopically transplanted into the infra-renal aorta of Lewis recipients and harvested at 28 or 56 days. Treated recipients received CP-690,550 by osmotic pumps (mean drug exposure of 110 ± 38 ng/ml). Significant intimal hyperplasia was demonstrated in untreated allografts when compared with isografts at 28 days (2.08 ± 0.85{\%} vs. 0.43 ± 0.2{\%} luminal obliteration, respectively, P = 0.001) and 56 days (5.3 ± 2.4{\%} vs. 0.38 ± 0.3{\%}, P = 0.002). Treatment caused a 51{\%} reduction in intimal hyperplasia at day 56. CP-690,550-treated animals also had a significant reduction of donor-specific IgG production and of the gene expression for suppressor of cytokine signaling-3 and with unchanged levels of expression of RANTES, IP-10 and transforming growth factor-β1. These results are the first to show that JAK3 blockade by CP-690,550 effectively prevents allograft vasculopathy in this rat model of aorta transplantation.",
keywords = "Aorta transplantation, Chronic rejection, CP-690,550, Janus kinase 3",
author = "Geraldine Rousvoal and Si, {Ming Sing} and Macy Lau and Sally Zhang and Berry, {Gerald J.} and Flores, {Mona G.} and Changelian, {Paul S.} and Reitz, {Bruce A.} and Borie, {Dominic C.}",
year = "2006",
month = "12",
doi = "10.1111/j.1432-2277.2006.00387.x",
language = "English (US)",
volume = "19",
pages = "1014--1021",
journal = "Transplant International",
issn = "0934-0874",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy

AU - Rousvoal, Geraldine

AU - Si, Ming Sing

AU - Lau, Macy

AU - Zhang, Sally

AU - Berry, Gerald J.

AU - Flores, Mona G.

AU - Changelian, Paul S.

AU - Reitz, Bruce A.

AU - Borie, Dominic C.

PY - 2006/12

Y1 - 2006/12

N2 - Janus kinase 3 (JAK3) mediates signal transduction from cytokine receptors using the common γ chain. The rationally designed inhibitor of JAK3, CP-690,550, prevents acute allograft rejection in rodents and in nonhuman primates. Here we investigated the ability of CP-690,550, to prevent allograft vasculopathy in a rodent model of aorta transplantation. Aortas from AxC Irish (RT1a) or Lewis (RT1l) rats were heterotopically transplanted into the infra-renal aorta of Lewis recipients and harvested at 28 or 56 days. Treated recipients received CP-690,550 by osmotic pumps (mean drug exposure of 110 ± 38 ng/ml). Significant intimal hyperplasia was demonstrated in untreated allografts when compared with isografts at 28 days (2.08 ± 0.85% vs. 0.43 ± 0.2% luminal obliteration, respectively, P = 0.001) and 56 days (5.3 ± 2.4% vs. 0.38 ± 0.3%, P = 0.002). Treatment caused a 51% reduction in intimal hyperplasia at day 56. CP-690,550-treated animals also had a significant reduction of donor-specific IgG production and of the gene expression for suppressor of cytokine signaling-3 and with unchanged levels of expression of RANTES, IP-10 and transforming growth factor-β1. These results are the first to show that JAK3 blockade by CP-690,550 effectively prevents allograft vasculopathy in this rat model of aorta transplantation.

AB - Janus kinase 3 (JAK3) mediates signal transduction from cytokine receptors using the common γ chain. The rationally designed inhibitor of JAK3, CP-690,550, prevents acute allograft rejection in rodents and in nonhuman primates. Here we investigated the ability of CP-690,550, to prevent allograft vasculopathy in a rodent model of aorta transplantation. Aortas from AxC Irish (RT1a) or Lewis (RT1l) rats were heterotopically transplanted into the infra-renal aorta of Lewis recipients and harvested at 28 or 56 days. Treated recipients received CP-690,550 by osmotic pumps (mean drug exposure of 110 ± 38 ng/ml). Significant intimal hyperplasia was demonstrated in untreated allografts when compared with isografts at 28 days (2.08 ± 0.85% vs. 0.43 ± 0.2% luminal obliteration, respectively, P = 0.001) and 56 days (5.3 ± 2.4% vs. 0.38 ± 0.3%, P = 0.002). Treatment caused a 51% reduction in intimal hyperplasia at day 56. CP-690,550-treated animals also had a significant reduction of donor-specific IgG production and of the gene expression for suppressor of cytokine signaling-3 and with unchanged levels of expression of RANTES, IP-10 and transforming growth factor-β1. These results are the first to show that JAK3 blockade by CP-690,550 effectively prevents allograft vasculopathy in this rat model of aorta transplantation.

KW - Aorta transplantation

KW - Chronic rejection

KW - CP-690,550

KW - Janus kinase 3

UR - http://www.scopus.com/inward/record.url?scp=33750600290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750600290&partnerID=8YFLogxK

U2 - 10.1111/j.1432-2277.2006.00387.x

DO - 10.1111/j.1432-2277.2006.00387.x

M3 - Article

VL - 19

SP - 1014

EP - 1021

JO - Transplant International

JF - Transplant International

SN - 0934-0874

IS - 12

ER -